The FDA has had a busy month, overseeing the recall of nearly 88,000 implantable cardiac devices, juggling the continued rise of monkeypox cases in the United States and maintaining an active Breakthrough Devices program. This rundown covers some of the agency's biggest moves during that time. 

The new hydrogel material was designed to immediately conform to the patient's body and create a barrier.

A two-medication strategy after CABG surgery reduces the risk that grafts will fail, but it also increases the risk of serious bleeding. As one surgeon said, "the benefit comes at a price.”

A new scientific statement details the most common symptoms associated with heart attacks, heart failure and other cardiac conditions. Importantly, the authors wrote, clinicians must remember that symptoms can vary between men and women. 

The company can now update its labeling instructions for the device to include a new 45-day dual anti-platelet therapy treatment option when treating non-valvular atrial fibrillation. 

A new meta-analysis of 28 different studies confirmed that robotic-assisted radical nephrectomy with IVC thrombectomy is a safe treatment option for kidney cancer.